Figure 8. The upregulating IL-6 secreted... | Rockefeller University Press

Figure 8.

The upregulating IL-6 secreted by Tet2−/−pMDMs activated HSCs in Tet2ΔMye-CCl4mice. (A) Effect of Tet2ΔMye on serum IL-6 levels evaluated by ELISA in oil- or CCl4-treated Tet2WT and Tet2ΔMye mice (n = 4 for each group). (B) Effect of Tet2ΔMye on Il-6 mRNA levels in livers of oil- or CCl4-treated Tet2WT and Tet2ΔMye mice (n = 4 for oil-treated groups, n = 5 for CCl4-treated groups). (C) Experimental design of co-culture between Tet2+/+ or Tet2−/− HSCs and Tet2+/+ or Tet2−/− pMDMs. Tet2+/+ and Tet2−/− pMDMs were isolated from livers of CCl4-treated Tet2WT and Tet2ΔMye mice. Naïve Tet2+/+ and Tet2−/− HSCs were isolated from oil-treated Tet2WT and Tet2ΔMye mice. (D) Detection of IL-6 in the supernatant after co-culture by ELISA (n = 3 for each group). (E–G) mRNA and protein levels of Acta2 (E and G) and Col1a1 (F and G) detected by RT-PCR in Tet2+/+ and Tet2−/− HSCs co-cultured with Tet2+/+ or Tet2−/− pMDMs (n = 3 for each group). (H and I) Picrosirius red staining (H) (scale bar, 125 μm) and statistical analysis (I) of livers of oil- or CCl4-treated Tet2WT and Tet2ΔMye mice after Bindarit plus anti-IL-6 Abs treatment (n = 4 for each group). (J and K) Changes in serum ALT (J) and AST (K) levels in CCl4-treated Tet2WT and Tet2ΔMye mice after treatment with Bindarit, anti–IL-6 Abs, or Bindarit plus anti–IL-6 Abs (n = 4 for each group). Data are representative of at least two independent experiments with similar results (A–K). All data are shown as mean ± SD and were analyzed by two-way ANOVA with Sidak’s multiple comparison test (A, B, D–F, and I–K). ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; P > 0.05 not significant (ns). Source data are available for this figure: SourceData F8.

The upregulating IL-6 secreted by Tet2 ^−/− pMDMs activated HSCs in Tet2 ^ΔMye -CCl ₄ mice. (A) Effect of Tet2^ΔMye on serum IL-6 levels evaluated by ELISA in oil- or CCl₄-treated Tet2^WT and Tet2^ΔMye mice (n = 4 for each group). (B) Effect of Tet2^ΔMye on Il-6 mRNA levels in livers of oil- or CCl₄-treated Tet2^WT and Tet2^ΔMye mice (n = 4 for oil-treated groups, n = 5 for CCl₄-treated groups). (C) Experimental design of co-culture between Tet2^+/+ or Tet2^−/− HSCs and Tet2^+/+ or Tet2^−/− pMDMs. Tet2^+/+ and Tet2^−/− pMDMs were isolated from livers of CCl₄-treated Tet2^WT and Tet2^ΔMye mice. Naïve Tet2^+/+ and Tet2^−/− HSCs were isolated from oil-treated Tet2^WT and Tet2^ΔMye mice. (D) Detection of IL-6 in the supernatant after co-culture by ELISA (n = 3 for each group). (E–G) mRNA and protein levels of Acta2 (E and G) and Col1a1 (F and G) detected by RT-PCR in Tet2^+/+ and Tet2^−/− HSCs co-cultured with Tet2^+/+ or Tet2^−/− pMDMs (n = 3 for each group). (H and I) Picrosirius red staining (H) (scale bar, 125 μm) and statistical analysis (I) of livers of oil- or CCl₄-treated Tet2^WT and Tet2^ΔMye mice after Bindarit plus anti-IL-6 Abs treatment (n = 4 for each group). (J and K) Changes in serum ALT (J) and AST (K) levels in CCl₄-treated Tet2^WT and Tet2^ΔMye mice after treatment with Bindarit, anti–IL-6 Abs, or Bindarit plus anti–IL-6 Abs (n = 4 for each group). Data are representative of at least two independent experiments with similar results (A–K). All data are shown as mean ± SD and were analyzed by two-way ANOVA with Sidak’s multiple comparison test (A, B, D–F, and I–K). ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; P > 0.05 not significant (ns). Source data are available for this figure: SourceData F8.